Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
@prefix fhir: <http://hl7.org/fhir/> . @prefix owl: <http://www.w3.org/2002/07/owl#> . @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> . @prefix xsd: <http://www.w3.org/2001/XMLSchema#> . # - resource ------------------------------------------------------------------- a fhir:Bundle ; fhir:nodeRole fhir:treeRoot ; fhir:id [ fhir:v "bundlepackageleaflet-en-a361de1944c94e68e8ec09dc10081b81"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi> ] ) ] ; # fhir:language [ fhir:v "en"] ; # fhir:identifier [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "None" ] ] ; # fhir:type [ fhir:v "document"] ; # fhir:timestamp [ fhir:v "2023-06-27T10:09:22Z"^^xsd:dateTime] ; # fhir:entry ( [ fhir:fullUrl [ fhir:v "Composition/composition-en-a361de1944c94e68e8ec09dc10081b81"^^xsd:anyURI ] ; ( fhir:resource <Composition/composition-en-a361de1944c94e68e8ec09dc10081b81> ) ] [ fhir:fullUrl [ fhir:v "MedicinalProductDefinition/mpa361de1944c94e68e8ec09dc10081b81"^^xsd:anyURI ] ; ( fhir:resource <MedicinalProductDefinition/mpa361de1944c94e68e8ec09dc10081b81> ) ] ) . # <Composition/composition-en-a361de1944c94e68e8ec09dc10081b81> a fhir:Composition ; fhir:id [ fhir:v "composition-en-a361de1944c94e68e8ec09dc10081b81"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi> ] ) ] ; # fhir:language [ fhir:v "en"] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-a361de1944c94e68e8ec09dc10081b81\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-a361de1944c94e68e8ec09dc10081b81</b></p><a name=\"composition-en-a361de1944c94e68e8ec09dc10081b81\"> </a><a name=\"hccomposition-en-a361de1944c94e68e8ec09dc10081b81\"> </a><a name=\"composition-en-a361de1944c94e68e8ec09dc10081b81-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/19/1386/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - deferasirox</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>" ] ; # fhir:identifier ( [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "EU/1/19/1386/001" ] ] ) ; # fhir:status [ fhir:v "final"] ; # fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "Package Leaflet" ] ] ; # fhir:category ( [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"^^xsd:anyURI ] ; fhir:code [ fhir:v "R" ] ; fhir:display [ fhir:v "Raw" ] ] ) ] ) ; # fhir:subject ( [ fhir:reference [ fhir:v "MedicinalProductDefinition/mpa361de1944c94e68e8ec09dc10081b81" ] ] ) ; # fhir:date [ fhir:v "2022-02-16T13:28:17Z"^^xsd:dateTime] ; # fhir:author ( [ fhir:reference [ fhir:v "Organization/mah-ema" ] ] ) ; # fhir:title [ fhir:v "TEST PURPOSES ONLY - deferasirox"] ; # fhir:attester ( [ fhir:mode [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/composition-attestation-mode"^^xsd:anyURI ] ; fhir:code [ fhir:v "official" ] ] ) ] ; fhir:time [ fhir:v "2022-02-16T13:28:17Z"^^xsd:dateTime ] ] ) ; # fhir:section ( [ fhir:title [ fhir:v "B. Package Leaflet" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "B. Package Leaflet" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>" ] ; fhir:emptyReason [ ( fhir:coding [ fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/list-empty-reason"^^xsd:anyURI ] ; fhir:code [ fhir:v "unavailable" ] ] ) ] ; ( fhir:section [ fhir:title [ fhir:v "Package leaflet: Information for the user" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "Package leaflet: Information for the user" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>" ] ] [ fhir:title [ fhir:v "What is in this leaflet" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "What is in this leaflet" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Deferasirox Mylan is and what it is used for</li><li>What you need to know before you take Deferasirox Mylan</li><li>How to take Deferasirox Mylan</li><li>Possible side effects</li><li>How to store Deferasirox Mylan</li><li>Contents of the pack and other information</li></ol></div>" ] ] [ fhir:title [ fhir:v "1. What deferasirox is and what it is used for" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "1. What deferasirox is and what it is used for" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Deferasirox Mylan is Deferasirox Mylan contains an active substance called deferasirox. It is an iron chelator which is a medicine used to remove the excess iron from the body (also called iron overload). It traps and removes excess iron which is then excreted mainly in the stools.</p><p>What Deferasirox Mylan is used for Repeated blood transfusions may be necessary in patients with various types of anaemia (for example thalassaemia, sickle cell disease or myelodysplastic syndromes (MDS)). However, repeated blood transfusions can cause a build-up of excess iron. This is because blood contains iron and your body does not have a natural way to remove the excess iron you get with your blood transfusions. In patients with non-transfusion-dependent thalassaemia syndromes, iron overload may also develop over time, mainly due to increased absorption of dietary iron in response to low blood cell counts. Over time, the excess iron can damage important organs such as the liver and heart. Medicines called iron chelators are used to remove the excess iron and reduce the risk of it causing organ damage.</p><p>Deferasirox Mylan is used to treat chronic iron overload caused by frequent blood transfusions in patients with beta thalassaemia major aged 6 years and older.</p><p>Deferasirox Mylan is also used to treat chronic iron overload when deferoxamine therapy is contraindicated or inadequate in patients with beta thalassaemia major with iron overload caused by infrequent blood transfusions, in patients with other types of anaemias, and in children aged 2 to 5 years.</p><p>Deferasirox Mylan is also used when deferoxamine therapy is contraindicated or inadequate to treat patients aged 10 years or older who have iron overload associated with their thalassaemia syndromes, but who are not transfusion dependent.</p></div>" ] ] [ fhir:title [ fhir:v "2. What you need to know before you take deferasirox" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "2. What you need to know before you take deferasirox" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do not take Deferasirox Mylan</p><p>if you are allergic to deferasirox or any of the other ingredients of this medicine (listed in section 6). If this applies to you, tell your doctor before taking Deferasirox Mylan. If you think you may be allergic, ask your doctor for advice.</p><p>if you have moderate or severe kidney disease.</p><p>if you are currently taking any other iron chelator medicines.</p><p>Deferasirox Mylan is not recommended</p><p>if you are at an advanced stage of myelodysplastic syndrome (MDS; decreased production of blood cells by the bone marrow) or have advanced cancer.</p><p>Warnings and precautions Talk to your doctor or pharmacist before taking Deferasirox Mylan:</p><p>if you have a kidney or liver problem.</p><p>if you have a cardiac problem due to iron overload.</p><p>if you notice a marked decrease in your urine output (sign of kidney problem).</p><p>if you develop a severe rash, or difficulty breathing and dizziness or swelling mainly of the face and throat (signs of severe allergic reaction, see also section 4 Possible side effects ).</p><p>if you experience a combination of any of the following symptoms: rash, red skin, blistering of the lips, eyes or mouth, skin peeling, high fever, flu-like symptoms, enlarged lymph nodes (signs of severe skin reaction, see also section 4 Possible side effects ).</p><p>if you experience a combination of drowsiness, upper right abdominal pain, yellowing or increased yellowing of your skin or eyes and dark urine (signs of liver problems).</p><p>if you experience difficulty thinking, remembering information, or solving problems, being less alert or aware or feeling very sleepy with low energy (signs of a high level of ammonia in your blood, which may be associated with liver or renal problems, see also section 4 Possible side effects ).</p><p>if you vomit blood and/or have black stools.</p><p>if you experience frequent abdominal pain, particularly after eating or taking Deferasirox Mylan.</p><p>if you experience frequent heartburn.</p><p>if you have a low level of platelets or white blood cells in your blood test.</p><p>if you have blurred vision</p><p>if you have diarrhoea or vomiting. If any of these apply to you, tell your doctor straight away.</p><p>Monitoring your Deferasirox Mylan treatment You will have regular blood and urine tests during treatment. These will monitor the amount of iron in your body (blood level of ferritin) to see how well Deferasirox Mylan is working. The tests will also monitor your kidney function (blood level of creatinine, presence of protein in the urine) and liver function (blood level of transaminases). Your doctor may require you to undergo a kidney biopsy, if he/she suspects significant kidney damage. You may also have MRI (magnetic resonance imaging) tests to determine the amount of iron in your liver. Your doctor will take these tests into consideration when deciding on the dose of Deferasirox Mylan most suitable for you and will also use these tests to decide when you should stop taking Deferasirox Mylan.</p><p>Your eyesight and hearing will be tested each year during treatment as a precautionary measure.</p><p>Other medicines and Deferasirox Mylan Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes in particular:</p><p>other iron chelators, which must not be taken with Deferasirox Mylan,</p><p>antacids (medicines used to treat heartburn) containing aluminium, which should not be taken at the same time of day as Deferasirox Mylan,</p><p>ciclosporin (used to prevent the body rejecting a transplanted organ or for other conditions, such as rheumatoid arthritis or atopic dermatitis),</p><p>simvastatin (used to lower cholesterol),</p><p>certain painkillers or anti-inflammatory medicines (e.g. aspirin, ibuprofen, corticosteroids),</p><p>oral bisphosphonates (used to treat osteoporosis),</p><p>anticoagulant medicines (used to prevent or treat blood clotting),</p><p>hormonal contraceptive agents (birth control medicines),</p><p>bepridil, ergotamine (used for heart problems and migraines),</p><p>repaglinide (used to treat diabetes),</p><p>rifampicin (used to treat tuberculosis),</p><p>phenytoin, phenobarbital, carbamazepine (used to treat epilepsy),</p><p>ritonavir (used in the treatment of HIV infection),</p><p>paclitaxel (used in cancer treatment),</p><p>theophylline (used to treat respiratory diseases such as asthma),</p><p>clozapine (used to treat psychiatric disorders such as schizophrenia),</p><p>tizanidine (used as a muscle relaxant),</p><p>cholestyramine (used to lower cholesterol levels in the blood),</p><p>busulfan (used as a treatment prior to transplantation in order to destroy the original bone marrow before the transplant),</p><p>midazolam (used to relieve anxiety and/or trouble sleeping).</p><p>Additional tests may be required to monitor the blood levels of some of these medicines.</p><p>Older people (age 65 years and over) Deferasirox Mylan can be used by people aged 65 years and over at the same dose as for other adults. Elderly patients may experience more side effects (in particular diarrhoea) than younger patients. They should be monitored closely by their doctor for side effects that may require a dose adjustment.</p><p>Children and adolescents Deferasirox Mylan can be used in children and adolescents receiving regular blood transfusions aged 2 years and over and in children and adolescents not receiving regular blood transfusions aged 10 years and over. As the patient grows the doctor will adjust the dose. Deferasirox Mylan is not recommended for children aged under 2 years. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>Deferasirox Mylan is not recommended during pregnancy unless clearly necessary.</p><p>If you are currently using a hormonal contraceptive to prevent pregnancy, you should use an additional or different type of contraception (e.g. condom), as Deferasirox Mylan may reduce the effectiveness of hormonal contraceptives.</p><p>Breast-feeding is not recommended during treatment with Deferasirox Mylan.</p><p>Driving and using machines If you feel dizzy after taking Deferasirox Mylan, do not drive or operate any tools or machines until you are feeling normal again.</p><p>Deferasirox Mylan contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium-free .</p></div>" ] ] [ fhir:title [ fhir:v "3. How to take deferasirox" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "3. How to take deferasirox" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Treatment with Deferasirox Mylan will be overseen by a doctor who is experienced in the treatment of iron overload caused by blood transfusions.</p><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>How much Deferasirox Mylan to take The dose of Deferasirox Mylan is related to body weight for all patients. Your doctor will calculate the dose you need and tell you how many tablets to take each day.</p><ul><li>The usual daily dose for Deferasirox Mylan film-coated tablets at the start of the treatment for patients receiving regular blood transfusions is 14 mg per kilogram body weight. A higher or lower starting dose may be recommended by your doctor based on your individual treatment needs.</li><li>The usual daily dose for Deferasirox Mylan film-coated tablets at the start of the treatment for patients not receiving regular blood transfusions is 7 mg per kilogram body weight.</li><li>Depending on how you respond to treatment, your doctor may later adjust your treatment to a higher or lower dose.</li></ul><p>The maximum recommended daily dose for Deferasirox Mylan film-coated tablets is:</p><ul><li>28 mg per kilogram body weight for patients receiving regular blood transfusions,</li><li>14 mg per kilogram body weight for adult patients not receiving regular blood transfusions,</li><li>7 mg per kilogram body weight for children and adolescents not receiving regular blood transfusions.</li></ul><p>Deferasirox also comes as dispersible tablets. If you are switching from the dispersible tablets to these film-coated tablets, you will need an adjustment of the dose.</p><p>When to take Deferasirox Mylan</p><ul><li>Take Deferasirox Mylan once a day, every day, at about the same time each day with some water.</li><li>Take Deferasirox Mylan film-coated tablets either on an empty stomach or with a light meal. Taking Deferasirox Mylan at the same time each day will also help you remember when to take your tablets.</li></ul><p>For patients who are unable to swallow whole tablets, Deferasirox Mylan film-coated tablets may be crushed and taken by sprinkling the full dose onto soft food such as yogurt or apple sauce (pureed apple). The food should be immediately and completely consumed. Do not store it for future use.</p><p>How long to take Deferasirox Mylan Continue taking Deferasirox Mylan every day for as long as your doctor tells you. This is a long- term treatment, possibly lasting for months or years. Your doctor will regularly monitor your condition to check that the treatment is having the desired effect (see also section 2: Monitoring your Deferasirox Mylan treatment ).</p><p>If you have questions about how long to take Deferasirox Mylan, talk to your doctor.</p><p>If you take more Deferasirox Mylan than you should If you have taken too much Deferasirox Mylan, or if someone else accidentally takes your tablets, contact your doctor or hospital for advice straight away. Show the doctor the pack of tablets. Urgent medical treatment may be necessary. You may experience effects such as abdominal pain, diarrhoea, nausea and vomiting and kidney or liver problems that can be serious.</p><p>If you forget to take Deferasirox Mylan If you miss a dose, take it as soon as you remember on that day. Take your next dose as scheduled. Do not take a double dose on the next day to make up for the forgotten tablet(s).</p><p>If you stop taking Deferasirox Mylan Do not stop taking Deferasirox Mylan unless your doctor tells you to. If you stop taking it, the excess iron will no longer be removed from your body (see also above section How long to take Deferasirox Mylan ).</p></div>" ] ] [ fhir:title [ fhir:v "4. Possible side effects" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "4. Possible side effects" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Most of the side effects are mild to moderate and will generally disappear after a few days to a few weeks of treatment.</p><p>Some side effects could be serious and need immediate medical attention. These side effects are uncommon (may affect up to 1 in 100 people) or rare (may affect up to 1 in 1,000 people).</p><ul><li>If you get a severe rash, or difficulty breathing and dizziness or swelling mainly of the face and throat (signs of severe allergic reaction),</li><li>If you experience a combination of any of the following symptoms: rash, red skin, blistering of the lips, eyes or mouth, skin peeling, high fever, flu-like symptoms, enlarged lymph nodes, (signs of severe skin reactions),</li><li>If you notice a marked decrease in your urine output (sign of kidney problem),</li><li>If you experience a combination of drowsiness, upper right abdominal pain, yellowing or increased yellowing of your skin or eyes and dark urine (signs of liver problems),</li><li>If you experience difficulty thinking, remembering information, or solving problems, being less alert or aware or feeling very sleepy with low energy (signs of a high level of ammonia in your blood, which may be associated with liver or renal problems and lead to a change in your brain function),</li><li>If you vomit blood and/or have black stools,</li><li>If you experience frequent abdominal pain, particularly after eating or taking Deferasirox Mylan,</li><li>If you experience frequent heartburn,</li><li>If you experience partial loss of vision,</li><li>If you experience severe upper stomach pain (pancreatitis), stop taking this medicine and tell your doctor straight away.</li></ul><p>Some side effects could become serious. These side effects are uncommon.</p><ul><li>If you get blurred or cloudy eyesight,</li><li>If you get reduced hearing, tell your doctor as soon as possible.</li></ul><p>Other side effects Very common (may affect more than 1 in 10 people)</p><ul><li>Disturbance in kidney function tests.</li></ul><p>Common (may affect up to 1 in 10 people)</p><ul><li>Gastrointestinal disorders, such as nausea, vomiting, diarrhoea, pain in the abdomen, bloating, constipation, indigestion</li><li>Rash</li><li>Headache</li><li>Disturbance in liver function tests</li><li>Itching</li><li>Disturbance in urine test (protein in the urine) If any of these affects you severely, tell your doctor.</li></ul><p>Uncommon (may affect up to 1 in 100 people)</p><ul><li>Dizziness</li><li>Fever</li><li>Sore throat</li><li>Swelling of arms or legs</li><li>Change in the colour of the skin</li><li>Anxiety</li><li>Sleep disorder</li><li>Tiredness If any of these affects you severely, tell your doctor.</li></ul><p>Frequency not known (cannot be estimated from the available data)</p><ul><li>A decrease in the number of cells involved in blood clotting (thrombocytopenia), in the number of red blood cells (anaemia aggravated), in the number of white blood cells (neutropenia) or in the number of all kinds of blood cells (pancytopenia)</li><li>Hair loss</li><li>Kidney stones</li><li>Low urine output</li><li>Tear in stomach or intestine wall that can be painful and cause nausea</li><li>Severe upper stomach pain (pancreatitis)</li><li>Abnormal level of acid in blood</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>" ] ] [ fhir:title [ fhir:v "5. How to store deferasirox" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "5. How to store deferasirox" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the blister/label and the carton after EXP . The expiry date refers to the last day of that month.</p><p>Do not use any pack that is damaged or shows signs of tampering. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>" ] ] [ fhir:title [ fhir:v "6. Contents of the pack and other information" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "6. Contents of the pack and other information" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Deferasirox Mylan contains The active substance is deferasirox.</p><ul><li>Each film-coated tablet of Deferasirox Mylan 90 mg contains 90 mg deferasirox.</li><li>Each film-coated tablet of Deferasirox Mylan 180 mg contains 180 mg deferasirox.</li><li>Each film-coated tablet of Deferasirox Mylan 360 mg contains 360 mg deferasirox.</li></ul><p>The other ingredients are microcrystalline cellulose, crospovidone, povidone, magnesium stearate, colloidal anhydrous silica and poloxamer. The tablet coating material contains: hypromellose, titanium dioxide (E171), macrogol/PEG (6000), talc, indigo carmine aluminium Lake (E132).</p><p>What Deferasirox Mylan looks like and contents of the pack Deferasirox Mylan is supplied as film-coated tablets.</p><ul><li><p>Deferasirox Mylan 90 mg film-coated tablets are blue, film-coated, modified capsule shaped, biconvex tablets debossed with<br/>on one side of the tablet and DF on the other side.</p></li><li><p>Deferasirox Mylan 180 mg film-coated tablets are blue, film-coated, modified capsule shaped, biconvex tablets debossed with<br/>on one side of the tablet and DF 1 on the other side.</p></li><li><p>Deferasirox Mylan 360 mg film-coated tablets are blue, film-coated, modified capsule shaped, biconvex tablets debossed with<br/>on one side of the tablet and DF 2 on the other side.</p></li></ul><p>Deferasirox Mylan is available in clear, transparent PVC/PVdC /aluminium blister packs containing or 90 film-coated tablets, in unit dose blister pack of 30 tablets and in white, plastic bottles with white opaque screw cap with aluminium seal containing 90 and 300 tablets. Deferasirox Mylan 360 mg film-coated tablets are also available in blister packs of 300 tablets. Not all pack sizes may be marketed. Marketing Authorisation Holder</p><p>Mylan Pharmaceuticals Limited Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland</p><p>Manufacturer</p><p>Mylan Hungary Kft., Mylan utca 1, Kom rom 2900, Hungary</p><p>McDermott Laboratories Limited t/a Gerard Laboratories t/a Mylan Dublin, Unit 35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13, Ireland</p><p>Mylan Germany GmbH, Zweigniederlassung Bad Homburg v. d. Hoehe Benzstrasse 1, Bad Homburg v. d. Hoehe, Hessen, 61352, Germany</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.</p><p>Belgi /Belgique/Belgien Mylan bvba/sprl T l/Tel: + 32 (0)2 658 61 Lietuva Mylan Healthcare UAB Tel: +370 5 205 1</p><p>: +359 2 44 55 Luxembourg/Luxemburg Mylan bvba/sprl T l/Tel: + 32 (0)2 658 61 (Belgique/Belgien)</p><p>esk republika Viatris CZ s.r.o. Tel: + 420 222 004 Magyarorsz g Mylan EPD Kft Tel: + 36 1 465 2Danmark Viatris ApS Tlf: +45 28 11 69 Malta V.J. Salomone Pharma Ltd Tel: + 356 21 22 01 Deutschland Viatris Healthcare GmbH<br/>Tel: +49 800 0700 Nederland Mylan BV Tel: +31 (0)20 426 3Eesti BGP Products Switzerland GmbH<br/>Eesti filiaal<br/>Tel: + 372 6363<br/>Generics Pharma Hellas<br/>: +30 210 993 6Norge Viatris AS Tlf: +47 66 75 33 sterreich Arcana Arzneimittel GmbH<br/>Tel: +43 1 416 2Espa a Viatris Pharmaceuticals, S.L.U.. Tel: + 34 900 102 Polska Mylan Healthcare Sp. z.o.o . Tel: + 48 22 546 64 France Viatris Sant<br/>T l : +33 4 37 25 75 Portugal Mylan, Lda. Tel: + 351 214 127 Hrvatska Mylan Hrvatska d.o.o. Tel: +385 1 23 50 Rom nia BGP Products SRL Tel: + 40 372 579 Ireland Mylan Ireland Limited Tel: +353 1 8711Slovenija Viatris d.o.o. Tel: + 386 1 23 63 slandIcepharma hf S mi: +354 540 8Slovensk republika Viatris Slovakia s.r.o. Tel: +421 2 32 199 Italia Mylan Italia S.r.l. Tel: + 39 02 612 46Suomi/Finland Viatris Oy Puh/Tel: +358 20 720 9<br/>Varnavas Hadjipanayis Ltd : + 357 2220 7Sverige Viatris AB Tel: + 46 (0) 8 630 19 Latvija Mylan Healthcare SIA Tel: +371 676 055 United Kingdom (Northern Ireland) Mylan IRE Healthcare Limited<br/>Tel: + 353 18711This leaflet was last revised in {MM/YYYY}.</p><p>Other sources of information Detailed information on this medicine is available on the European Medicines Agency website: <a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a>.</p></div>" ] ] ) ] ) . # <MedicinalProductDefinition/mpa361de1944c94e68e8ec09dc10081b81> a fhir:MedicinalProductDefinition ; fhir:id [ fhir:v "mpa361de1944c94e68e8ec09dc10081b81"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi> ] ) ] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mpa361de1944c94e68e8ec09dc10081b81\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mpa361de1944c94e68e8ec09dc10081b81</b></p><a name=\"mpa361de1944c94e68e8ec09dc10081b81\"> </a><a name=\"hcmpa361de1944c94e68e8ec09dc10081b81\"> </a><a name=\"mpa361de1944c94e68e8ec09dc10081b81-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/19/1386/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Deferasirox Mylan 90 mg film-coated tablets</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>" ] ; # fhir:identifier ( [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "EU/1/19/1386/001" ] ] ) ; # fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/medicinal-product-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "MedicinalProduct" ] ; fhir:display [ fhir:v "Medicinal Product" ] ] ) ] ; # fhir:domain [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/medicinal-product-domain"^^xsd:anyURI ] ; fhir:code [ fhir:v "Human" ] ; fhir:display [ fhir:v "Human use" ] ] ) ] ; # fhir:status [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/publication-status"^^xsd:anyURI ] ; fhir:code [ fhir:v "active" ] ; fhir:display [ fhir:v "active" ] ] ) ] ; # fhir:legalStatusOfSupply [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000072084" ] ; fhir:display [ fhir:v "Medicinal product subject to medical prescription" ] ] ) ] ; # fhir:name ( [ fhir:productName [ fhir:v "Deferasirox Mylan 90 mg film-coated tablets" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000001" ] ; fhir:display [ fhir:v "Full name" ] ] ) ] ; ( fhir:part [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000002" ] ; fhir:display [ fhir:v "Invented name part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000003" ] ; fhir:display [ fhir:v "Scientific name part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000004" ] ; fhir:display [ fhir:v "Strength part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000005" ] ; fhir:display [ fhir:v "Pharmaceutical dose form part" ] ] ) ] ] ) ; ( fhir:usage [ fhir:country [ ( fhir:coding [ fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ; fhir:code [ fhir:v "EU" ] ; fhir:display [ fhir:v "EU" ] ] ) ] ; fhir:jurisdiction [ ( fhir:coding [ fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ; fhir:code [ fhir:v "EU" ] ; fhir:display [ fhir:v "EU" ] ] ) ] ; fhir:language [ ( fhir:coding [ fhir:system [ fhir:v "urn:ietf:bcp:47"^^xsd:anyURI ] ; fhir:code [ fhir:v "en" ] ; fhir:display [ fhir:v "en" ] ] ) ] ] ) ] ) . #
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
